Quantitative analysis for Dr. Reddy's Laboratories Limited (RDY) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Unrated (50.0). 27 signals analyzed (24 differentiated alt-data).
RDY stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $13.95 | $13.69 | $13.73 |
| 2026-05-11 | $13.29 | $13.11 | $13.14 |
| 2026-05-21 | $13.61 | $13.42 | $13.55 |
| 2026-06-03 | $13.07 | $12.96 | $13.02 |
| 2026-06-15 | $13.43 | $13.32 | $13.33 |
| 2026-06-26 | $15.67 | $15.30 | $15.38 |
| 2026-07-09 | $14.06 | $13.57 | $13.89 |
| 2026-07-21 | $12.61 | $12.39 | $12.56 |
| 2026-07-31 | $11.86 | $11.72 | $11.85 |
| 2026-08-12 | $12.42 | $12.32 | $12.39 |
| 2026-08-24 | $12.25 | $12.13 | $12.22 |
| 2026-09-03 | $12.17 | $11.92 | $12.03 |
How Dr. Reddy's Laboratories Limited stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| FMS | Fresenius Medical Care AG & Co. KGaA | $12.0B | — |
| SNN | Smith & Nephew plc | $13.2B | — |
| ICLR | ICON Public Limited Company | $8.8B | — |
| ASND | Ascendis Pharma A/S | $14.9B | — |
View all Health Care stocks by valuation and signals →
Dr. Reddy's Laboratories Limited (RDY) scores Unrated (50.0), and the composite conceals a 69-point disagreement between its dimensions. It is strongest on analyst consensus at 85, and weakest on technicals at 16. A stock can carry analyst consensus that high while technicals sits at 16; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 85 |
| technicals | 16 |
StoQuant analyzes 27 signals (24 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Dr. Reddy's Laboratories Limited (RDY): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/RDY"><img src="https://stoquant.com/badge/RDY.svg" alt="Dr. Reddy's Laboratories Limited (RDY) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.